4030 Fabian Way
About Immune-Onc Therapeutics
Immune-Onc Therapeutics (“Immune-Onc”) is a newly established biopharmaceutical company focused on developing innovative therapeutic antibodies for cancer treatment. The Company is applying the latest scientific insights and expertise in drug development to advance novel immuno-oncology products and bring new treatment options to cancer patients.
Founders: Guo Liang Yu and Charlene Liao
14 articles with Immune-Onc Therapeutics
Immune-Onc Therapeutics Announces Orphan Drug Designation of IO-202 (Anti-LILRB4) for Treatment of AML and Poster Presentation at ASH 2020
Trials in Progress” poster presentation at the American Society of Hematology (ASH) Annual Meeting to detail mechanisms of action, preclinical data and trial design – – IO-202, targeting the immune inhibitory receptor LILRB4 (also known as ILT3), is being evaluated in a Phase I trial for acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML) –
Immune-Onc Therapeutics to Present Preclinical Data for IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4) in Solid Tumors, at SITC 2020
Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company, will present preclinical data evaluating IO-108, a novel antagonist antibody targeting the myeloid checkpoint Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2, also known as ILT4) for the treatment of solid tumors, at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting & Pre-Conference Programs (S
Immune-Onc Therapeutics Announces First Patient Dosed in Phase I Trial Evaluating IO-202, a First-In-Class Antibody for the Treatment of Acute Myeloid Leukemia
Sept. 16, 2020 11:45 UTC -- First-In-Human Trial Targeting the Immune Inhibitory Receptor, LILRB4 -- -- Preclinical Data Show LILRB4 Plays a Role in Immune Suppression and Tumor Infiltration -- PALO ALTO, Calif.--( BUSINESS WIRE )-- Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a cancer immunotherapy company focused on developing first-in-class biotherapeutics that target novel immunosuppressive myeloid checkpoints, announced today that the first patient has been dos
Immune-Onc Therapeutics Awarded $2.14 Million National Cancer Institute SBIR Grant to Support Development of IO-202, a First-in-Class Antibody Targeting LILRB4
Immune-Onc Therapeutics, Inc., a clinical-stage cancer immunotherapy company, announced it has been awarded a Small Business Innovation Research Direct to Phase II grant from the National Cancer Institute of the National Institutes of Health.
Immune-Onc Therapeutics IND Application for First-In-Human Trial of IO-202, a Novel Antibody for the Treatment of Acute Myeloid Leukemia, Receives FDA Clearance
Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company, announced today that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for IO-202, an antibody targeting an immune inhibitory receptor LILRB4. IO-202 is the first T-cell activator for a
Immune-Onc Therapeutics, Inc. is a privately held cancer immunotherapy company dedicated to the discovery and development of novel biologic treatments for cancer patients.
Immune-Onc Therapeutics Prepares for its Next Phase of Growth with New Leadership Appointments and Key Board Member Additions
Dr. Paul Woodard joins Immune-Onc from Bellicum Pharmaceuticals, Inc. where he most recently served as Senior Vice President, Clinical and Medical Affairs.
Immune-Onc Therapeutics (“Immune-Onc”), a privately held cancer immunotherapy company dedicated to the discovery and development of novel biologic treatments for cancer patients, today announced the appointments of Dr. Adrian Jubb as Chief Medical Officer and of Dr. An Song as Senior Vice President of Development Sciences.
Immune-Onc Therapeutics launched in September 2016 and is headquartered in Palo Alto, California.
BioSpace is proud to present its NextGen "Class of 2018," a list of 20 up-and-coming life science companies in North America that started up no earlier than 2015.
Immune-Onc Therapeutics Announces Partnership With University of Texas To Develop Novel Cancer Immunotherapy
Immune-Onc Therapeutics Announces Licensing And Collaboration With Albert Einstein College of Medicine And Memorial Sloan-Kettering Cancer Center To Develop Novel Cancer Immunotherapy